Oyster Point Pharma announced the appointment of Dan Lochner, MBA, as its Chief Financial Officer, and John Snisarenko, MBA, as Chief Commercial Officer.
Mr. Lochner joins Oyster Point Pharma after spending nearly 15 years, most recently as a Managing Director, at Goldman Sachs asset management focused on healthcare equity investing and fund management.
“Dan’s appointment comes at a pivotal time for Oyster Point as we grow the organization and advance our lead asset OC-01 for dry eye disease in phase 3 clinical trials and develop transformative treatments to address diseases of the ocular surface. His financial and investment acumen is a tremendous asset,” Jeffrey Nau, PhD, MMS, President and Chief Executive Officer at Oyster Point Pharma, said in a company news release.
Mr. Lochner brings a unique perspective to the business based on his extensive experience investing in pharmaceutical and biotechnology companies similar to Oyster Point Pharma while at Goldman Sachs. Mr. Lochner reports to Dr. Nau.
“I am honored to join the Oyster Point team at this exciting point in the growth and evolution of our business,” Mr. Lochner, said in the news release. “We have a solid business foundation, a growing pipeline and a strong cash position to support organic and inorganic growth opportunities. I am excited to be working with the Oyster Point management team.”
Mr. Snisarenko joins Oyster Point Pharma from Shire (now Takeda) where he served as Group Vice President and Head of its ophthalmic business. Mr. Snisarenko brings extensive experience successfully leading the commercialization of new market entries and expanded indications for approved products. He has led commercial strategy and sales and marketing teams for multiple commercial products, including Xiidra, Lucentis, Rituxan, and Actemra with a demonstrated track record of building high performing teams and generating robust sales growth in highly competitive markets.
“The addition of John to Oyster Point adds seasoned leadership and deep expertise in the commercialization of ophthalmic products. His experience is critical for successfully building our commercial organization as we prepare to launch our lead asset for dry eye disease and expand our product offering to address the high unmet need for patients with ocular surface diseases,” stated Dr. Nau.
Mr. Snisarenko brings vast experience in pharmaceutical and biotechnology leadership to the company. He is responsible for all commercial strategy and execution for Oyster Point Pharma’s growing clinical portfolio, including the launch of OC-01 for dry eye disease, if approved by the FDA. Mr. Snisarenko reports to Dr. Nau.
“I’m delighted to join Oyster Point and work with this dedicated team to bring such an innovative treatment as OC-01 to patients with Dry Eye Disease,” said Mr. Snisarenko. “I am impressed with the clinical data to date from the OC-01 clinical trials, and am excited to be able to leverage my experience to build the commercial organization and bring our innovative pipeline to our customers.”